Target identification is the first and perhaps most critical step in drug discovery and development. Although the human genome contains roughly 20,000 protein-coding genes, only about 4,500 are ...

While AI technology is new, information warfare is as old as conflict itself. For millennia, humans have used propaganda, ...

Vulcan Value Partners reviews the Focus Plus strategy for Q1 2026, highlighting new positions in TransUnion and SAP SE. Read ...

Vulcan Value Partners' Focus strategy reported a -19.1% net return for Q1 2026 while adding positions in TransUnion and SAP ...

New research shows how certain orphan noncoding RNA — oncRNA — can be predictable enough to be a ‘bar code’ identifying ...

The global biobanking market is projected to reach around US$53 billion by 2027, expanding at a growth rate of approximately 8%. Market growth is driven by rapid advancements in genomic research, a ...

If AI can rebalance a portfolio in seconds, do you still really need a human adviser to manage a nine figure fortune? Here, ...

War risk, tariff shocks and rerouted trade are reshaping where port capital goes and what it buys. Based on GlobalData’s port ...

Sean Kelly, MD, chief medical officer at Imprivata, reflects on the necessary considerations around the deployment of agentic ...

The ventral tegmental area (VTA) is a key site for opioid actions, and emerging evidence suggests that pain states and opioid experience both induce transcriptional, molecular, and circuit adaptations ...

Ever wonder why you have too much of what you don't need and none of what you do? It's likely because your planning system is ...

The biotech sector is transitioning away from a framework dominated by long-term research spending toward one in which scientific progress can be directly reflected in financial valuation. As drug ...